Published in 2016 – Ann Oncol (2016) 27 (suppl 5): v91-v102
Authors: U. Vitolo, J. F. Seymour, M. Martelli, G. Illerhaus, T. Illidge, E. Zucca, E. Campo and M. Ladetto
Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. Most DLBCLs originate in lymph nodes, but ≤40% initially present in extranodal sites. Differences in molecular pathogenesis, clinical presentation and natural history indicate that extranodal DLBCLs are distinct entities. These new ESMO Clinical Practice Guidelines provide practical clinical guidance and recommendations for the management of diffuse large B-cell lymphomas that arise in extranodal sites, including screening and diagnosis, staging and risk assessment and treatment strategies for primary testicular, central nervous system, breast and bone lymphomas.